
Trump Wants Saudi Arabia to Invest Its Money in the U.S. All of It.
President Trump embarks on a visit to Saudi Arabia on Tuesday with a $1 trillion wish list for investments in the United States — a sum equivalent to the kingdom's entire gross domestic product last year.
The Saudi crown prince is offering $600 billion during Mr. Trump's presidency.
Neither figure is realistic, economists say.
With a laundry list of its own costly megaprojects to build and with oil prices well below the level needed to finance its spending, Saudi Arabia is facing a budget deficit that could balloon to more than $70 billion this year. It is increasingly borrowing money rather than lending it.
But that did not stop Crown Prince Mohammed bin Salman, the de facto leader of the authoritarian Saudi monarchy, from pledging in January to invest $600 billion in the United States while Mr. Trump is in office. Not long after that, Mr. Trump called him a 'fantastic guy.'
Then the president said he would ask the crown prince to round that figure up to $1 trillion. And bring down the price of oil — the source of the kingdom's vast wealth — to boot.
'We've been very good to them,' Mr. Trump said.
Economists said that Saudi investments in the United States would probably increase during Mr. Trump's administration, but were unlikely to even approach $1 trillion.
The figure Mr. Trump is seeking exceeds the value of all assets in the kingdom's hefty sovereign wealth fund, which is worth about $925 billion and largely tied up in domestic holdings.
'I don't see how they get anywhere close to $600 billion, let alone $1 trillion,' said Tim Callen, an economist and former International Monetary Fund mission chief to Saudi Arabia.
In fact, at the crown prince's flagship investment forum in October, Yasir al-Rumayyan, head of the Saudi sovereign wealth fund, said he was aiming to decrease the percentage of the fund's assets that were invested abroad.
'We're more focused on the domestic economy,' he said, calling this a 'big paradigm shift.'
But for Mr. Trump and Prince Mohammed, these finer details are not necessarily the point. They speak the same language, Mr. Callen said, describing them as 'two guys who like throwing very large numbers around.'
Mr. Trump has cultivated strong business ties with Saudi Arabia. During his first term, his son-in-law and adviser Jared Kushner, developed a close relationship with Prince Mohammed and the two shared a transactional mind-set.
Mr. Trump and the Saudi crown prince both have a penchant for eye-popping declarations, leaving questions about feasibility for their underlings to sort out.
In some cases, Prince Mohammed's grand pronouncements have come to fruition. He has rapidly loosened social restrictions in the once-ultraconservative kingdom, enabling women to pour into the labor force and teenagers to dance at raves in the desert. Other plans, such as a $200 billion solar energy project that would have been the largest in the world, have been quietly swept aside.
Mr. Trump has claimed that, during his 2017 Saudi visit, he secured $450 billion of investments in the United States. But Mr. Callen said he analyzed public data and determined this amount did not fully materialize.
The export of American goods and services to Saudi Arabia while Mr. Trump was in office from 2017 to 2020 totaled $92 billion, Mr. Callen found, less than the total during President Barack Obama's second term, which ended in 2017.
Asked about this discrepancy and about Mr. Trump's target of securing $1 trillion in investments on the coming visit, the White House communications director Steven Cheung said that the president 'has already successfully secured more than $5 trillion in new investments into the U.S. economy — bringing manufacturing, boosting production, and creating high-paying jobs.'
Mr. Trump has said that it was the prospect of hundreds of billions of dollars in investments that prompted him to prioritize Saudi Arabia to kick off his first major overseas tour of this term — as he did in 2017 during his first term.
After Saudi Arabia, the president will visit two other wealthy Gulf allies on this trip, Qatar and the United Arab Emirates.
His state visit to Saudi Arabia this week is expected to be a spectacular affair, full of pageantry that contrasts sharply to President Joseph R. Biden Jr.'s relatively chilly visit to the kingdom in 2022.
During Mr. Trump's first Saudi state visit, he was welcomed with a traditional sword dance and an image of his face projected onto the facade of the lavish Ritz-Carlton hotel in Riyadh, the capital.
As they did last time, Saudi officials are planning to announce a flurry of deals after the president arrives.
The government is hosting an investment forum on Tuesday with a long roster of American business leaders, including the chief executives of IBM, BlackRock and Citigroup. Many of them already have Saudi ties.
This month, the State Department announced that it had approved a potential sale of $3.5 billion of air-to-air missiles to Saudi Arabia. A memorandum of understanding with the U.S. over mining and mineral resources is also expected.
Some deals could be tentative agreements that never materialize. Others could repackage previous deals, something that could serve to pad the total figure of investments that Mr. Trump can say he secured.
Saudi Arabia is still the world's largest oil exporter, bringing in hundreds of billions of dollars in revenue each year. Its U.S. investments are extensive, including more than $100 billion of Treasury holdings and $2 billion in a fund managed by Mr. Kushner.
Overall, the Saudi sovereign wealth fund has invested $110 billion in the United States since 2017, plus another $58 billion of procurement spending, the fund said in a statement to The Times. It did not respond to questions about expanding its investments in the country and the Saudi Finance Ministry also did not respond to a request for comment on the topic.
The Saudi state spends much of its revenue on public sector salaries. And under Prince Mohammed, it has invested in a growing number of domestic megaprojects.
The government is predicting budget deficits through at least 2027.
The costliest megaproject is Neom, the prince's crown jewel. It is an entire new region that he wants to build in the remote northwestern corner of the kingdom, with a mountain ski town and a skyscraper that stretches horizontally for 100 miles.
When he announced Neom in 2017, he called it a $500 billion project. But estimates of its potential cost have since soared into the trillions, and $50 billion has already been spent on the basic infrastructure alone.
Diriyah Gate, a vast culture and tourism hub in Riyadh, is now forecast to cost more than $60 billion, a number that has ballooned from early estimates of $20 billion. A luxury tourism project on the Red Sea has already cost more than $20 billion.
The kingdom also plans to host the World Expo in 2030 and the men's soccer World Cup in 2034 — both events that will require hefty spending on infrastructure.
Accounting for spending by its sovereign wealth fund, Saudi Arabia needs oil prices at about $108 a barrel for the state to simply break even, said Ziad Daoud, Bloomberg's chief emerging-market economist. The price of Brent crude is currently hovering above $60 a barrel.
Saudi officials could invest large sums in the United States, but they would need to borrow to do it, Mr. Daoud said.
'And $1 trillion is far-fetched,' he added.
Many people think of Saudi Arabia as a country 'that gives grants and loans and investments,' but that has changed, Mr. Daoud said.
To invest more in the United States, Saudi officials could also rebalance their portfolio — perhaps by selling assets in other countries, said Farouk Soussa, a Middle East economist at Goldman Sachs. But it is improbable that they could free up $1 trillion.
Mr. Soussa estimated that the kingdom's total assets abroad were about $1.4 trillion, much of which is already in the United States.
'How much is available to shift into the U.S. is anyone's guess,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
31 minutes ago
- Forbes
Billion-Dollar Breakthroughs: Inside The Global Race To Extend Human Healthspan
Hevolution CEO Dr. Mehmood Khan in conversation with GSK Chair Sir Jonathan Symonds In a luxurious conference center buzzing with Nobel laureates, biotech executives and Saudi royalty, one number kept surfacing during presentations: eight billion. Not dollars—though investment figures approached that scale—but people. The potential market for healthspan technologies encompasses every human on earth, creating what might be the ultimate investment opportunity of the 21st century. At the Hevolution Global Healthspan Summit 2025, the world's largest gathering for healthspan science, the discussion wasn't if humans could live longer, healthier lives, but how quickly we could make it happen. "I'm a firm believer, when you put several hundred scientists collectively working in a connected manner in the world, not in any one country, but in the world, from the west to the east, to solve a common challenge, that is how you put a man on the moon," declared Dr. Mehmood Khan, CEO of Hevolution. "That is your moonshot." Hevolution is a first of its kind global non-profit organization incentivizing independent research and entrepreneurship in the emerging field of healthspan science. The urgency behind this global mobilization is clear. Dr. Anshu Banerjee, Director at the World Health Organization, presented sobering statistics: "The number of older people above 60 is going to double by 2050, from 1.1 billion to 2.1 billion, and soon we'll have more people above 60 than under 10." Even more concerning: "Life expectancy is increasing, but healthspan is actually worsening. The increase in healthy life expectancy is not following the same pace as life expectancy overall." Global Lifespan versus Global Healthspan Women face particular challenges in this equation. While they "live longer than men," Banerjee noted they "spend more years in poor health," with the healthspan gap between genders widening since 2002. While American researchers navigate the FDA's complex pathway, Saudi Arabia is positioning itself as the global accelerator for healthspan innovations. His Excellency, addressing attendees, detailed the kingdom's "Innovation Pathways" designed for rapid approval of promising medicines, AI systems, and medical devices. This regulatory agility represents a strategic advantage in what has become a geopolitical race to commercialize healthspan technologies. With "maturity level four" recognition from the WHO and pending "world listed Authority" status, Saudi Arabia is creating an ecosystem where longevity science can flourish without traditional regulatory bottlenecks. The summit's scientific presentations ventured far beyond traditional human-centered research. Comparative biology—studying extraordinarily long-lived species like bowhead whales that can live over 200 years—emerged as a frontier with untapped potential. "These are models of disease resistance, healthspan, and lifespan," explained Dr. Vera Gorbunova, whose work on naked mole rats has revealed remarkable cancer resistance mechanisms. Pedro Magalhães, developer of a comprehensive database tracking lifespans across species, argued that understanding "why we live as long as we live" requires examining the evolutionary innovations that allow certain animals to far outlive humans. This approach faces funding challenges, however. Despite promising discoveries, researchers called for "more consortia" and a "big effort in comparative biology of aging" to translate animal longevity secrets into human applications. The unexpected star of the summit wasn't a new compound but an existing class of medications: GLP-1 agonists, originally developed for diabetes and now famous for weight loss. Dr. Christoph Westphal, co-founder of Longwood Fund, made a stunning prediction: "If all of us in this room, within three or four or five years, can prove that with GLP-1s you can extend healthy lifespan, it will actually be the first healthy lifespan increasing drug available. It's going to totally change the world." Westphal's enthusiasm reflects a paradigm shift in longevity research. "If you had told me that you would take something that has an effect in the brain and all over the body, and it's perfectly safe and it actually makes you live longer, I would have said, no way. But that's exactly what a GLP-1 is." The lesson for investors is clear, according to Dr. Srinivas Akkaraju of Samsara BioCapital: "A drug that shows measurable effects in a modest time with a modest number of patients can lead to longer studies for confirmation." The challenge is finding "near- to medium-term measurements that de-risk the investment." Perhaps the summit's most ambitious initiative is already underway in the UK. Professor Rahid Ali's "Our Future Health" program has collected data from over 1.5 million participants, with 1.3 million providing blood samples, making it the "world's largest health research study of its type." By deploying collection points in everyday locations like supermarkets and pharmacies, the program has democratized participation across socioeconomic and ethnic backgrounds. The goal: five million participants creating an unprecedented dataset that could reveal the early signals of disease and the effectiveness of preventative interventions. Notably, Ali reported that "about 80% of the general population, once they understand the importance of working with industry, are willing to participate" despite growing privacy concerns around health data. "We're investing across the entire value chain, from idea all the way into clinical trials and beyond," explained a senior Hevolution executive. The foundation isn't just writing checks—it's creating an "action shop and a money shop" designed to shepherd promising longevity science from laboratory concepts to market-ready interventions. Dr. William Greene, Chief Investment Officer at Hevolution Foundation, emphasized the need to "invest in translation, since there's a valley of death between interesting laboratory observation and something that seems to actually impact health." The goal is finding "the outcome that we're looking for that will actually make humans into big mice"—transitioning laboratory findings into human benefits. This fundamental challenge was echoed by Dr. Jarod Rutledge: "If you're trying to do genomic management, or something that's purely preventative, commercial models are very challenging, but if you can start from a state of disease and walk all the way back to state of youthful health, then I think that is really promising." In an industry where early adopters could pay millions for unproven therapies, Hevolution's emphasis on global equity stood out. Arthur Caplan, head of medical ethics at NYU Grossman School of Medicine, emphasized that proposals undergo rigorous ethical review centered on one question: "Is the science good, but can it help fulfill the commitment to benefit all?" This principle—extending healthspan advancements to "all of human humanity" rather than creating a longevity gap between wealthy and developing nations—appears foundational to Hevolution's approach. HRH Dr. Haya Al Saud, SVP of Research at Hevolution, outlined the broader societal benefits: "First, we'll be able to reduce healthcare costs. Healthcare spending is skyrocketing worldwide, so this is a crucial and immediate impact. Second, we can tackle the workforce challenge we're seeing today... If we're able to extend healthspan, people can live—and work—longer, in good health." Dr. Haya at Global Healthspan Summit 2025. She also highlighted a surprising social benefit: "Many women leave the workforce because they are the primary caregivers for sick family members. By extending healthspan, we can support and encourage women to remain in the workforce." The summit highlighted how philanthropic organizations are evolving from passive funders to active ecosystem builders. Her Royal Highness Princess Dr. Haya bint Khaled Al Saud described philanthropy as a "catalyst for change" in the healthspan field. Yet Dr. Khan insists that true global access requires commercial involvement: "I do not believe there is an example, other than maybe mass polio vaccine campaigns, where the public sector can, on its own, democratize something. Every example I can think of in democratization has happened because the private sector figured out how to get something into the hands of as many people as possible." He added a historical perspective: "Government invented the internet, the private sector scaled it, and then leveraged it for core commerce." As Dr. Khan concluded the summit, he emphasized that it's not heroic individuals but collective wisdom that will transform aging: "It is not heroes that we are developing. It is the future of this collective wisdom that we're actually investing behind, because it's going to take the village, not a hero." The fundamental question remains: Can we translate scientific breakthroughs into practical interventions that meaningfully extend the healthy human lifespan? The convergence of unprecedented funding, regulatory innovation, massive datasets, and ethical frameworks suggests we're entering a new phase in longevity science—one where theory meets application. Whether the first beneficiaries emerge from clinical trials in Riyadh, research labs in Boston, or digital health platforms in London remains to be seen. What's clear is that the race for extended healthspan has evolved from fringe science to mainstream pursuit. With eight billion potential customers waiting, the winners stand to transform not just healthcare, but the fundamental human experience of aging itself.


Fox News
40 minutes ago
- Fox News
Washington Post admits to faulty reporting on claim that Israel killed dozens of Gazan civilians at aide site
The Washington Post admitted Tuesday that a claim in its recent report that Israeli soldiers killed dozens of civilians in Gaza could not be verified. The outlet shared a post on X stating it had updated its Sunday article to reflect that it could not verify that Israeli troops killed around 30 civilians near a U.S. aid site in Gaza. The previous version of the piece reported that the Israeli military had committed the killings. "The article and headline were updated on Sunday evening making it clear that there was no consensus about who was responsible for the shootings and that there was a dispute over that question," the outlet's social media post read. At least 26 Palestinians were reportedly killed and some 175 were wounded over the weekend as they made their way to receive food in the Gaza Strip, according to officials from the Hamas-run health ministry and witnesses. Witnesses said Israeli forces fired on crowds around 1,000 yards away from an aid site run by the Israeli-backed Gaza Humanitarian Foundation (GHF). A Palestinian journalist told the BBC that thousands of Palestinians had gathered near the aid site near Gaza's southern city of Rafah when Israeli tanks approached and opened fire on the crowd. However, the IDF has disputed these allegations, saying they are "currently unaware of injuries caused by IDF fire within the Humanitarian Aid distribution site," adding that "the matter is still under review." "It is false and fabricated. All aid was distributed today without incident," the GHF said. "No injuries or fatalities as noted in our daily update sent out earlier. We have heard that these fake reports have been actively fomented by Hamas. They are untrue and fabricated." However, as an editor's note in the updated Washington Post piece said, The Post had reported on Sunday that "Israeli troops had killed more than 30 people near a U.S. aid site, with the headline attributing the action to 'health officials.'" "The article failed to make clear if attributing the deaths to Israel was the position of the Gaza health ministry or a fact verified by The Post," the note read. The body of the updated piece reported the casualties, but this time, did not blame the IDF. It said, "At least 31 people were killed and another 170 wounded, most of them with gunshot wounds to the extremities and upper body, according to local health officials and medics who treated the victims." "While three witnesses said the gunfire came from Israeli military positions, the Israel Defense Forces denied the allegations, saying in a statement that an initial inquiry indicated that its soldiers did not fire at civilians while they were near or within the distribution site," the new piece added. The editor's note confirmed that "The article and headline were updated on Sunday evening and for the print edition on Monday making it clear that there was no consensus about who was responsible for the shooting and that there was a dispute over that question." It added, "The Post didn't give proper weight to Israel's denial and gave improper certitude about what was known about any Israeli role in the shootings. The early versions fell short of Washington Post standards of fairness and should not have been published in that form." Reps for The Washington Post did not immediately reply to Fox News Digital's request for additional comment.


New York Times
an hour ago
- New York Times
The U.S. Proposed New Terms in Nuclear Talks With Iran
President Trump's envoy to the Middle East crafted the outline of a potential nuclear arrangement with Iran that was handed over to officials in Tehran over the weekend. Under the terms of the proposal, Iran would continue to enrich uranium at low levels while the U.S. and other countries work out a more detailed plan to block Iran's path to a nuclear weapon. The proposal amounts to a bridge between the current situation, in which Iran is rapidly producing near-bomb-grade uranium, and the U.S. goal of Iran enriching no uranium at all on its soil. It is the first concrete indication since Trump took office that the U.S. and Iran might be able to find a compromise. Officials in Tehran indicated that a response would come in several days. A breakthrough would be an unexpected twist in the president's diplomatic approach: After pulling out of the Obama-era Iran nuclear deal, he ordered the killing of Iran's highest-ranking generals. Iran, in return, has been accused of hiring assassins to kill Trump during his 2024 campaign. However, some details of a potential future deal remain vague, and the two sides are far apart on many issues. Just yesterday, Trump said he would 'not allow any enrichment of uranium' in Iran. In other Trump administration news: Elon Musk attacked Trump's domestic policy bill, calling it a 'disgusting abomination.' Another critic of the bill, Senator Rand Paul, was bashed by the president: 'His ideas are actually crazy (losers!)' Trump said. The White House unveiled a new, darker presidential portrait. Want all of The Times? Subscribe.